Therapeutic targeting of IL-6 or progranulin via their common receptor, sortilin, could be a potential novel treatment strategy for cancer forms with high levels of IL-6 or progranulin, inhibiting cancer stem cell functions and consequently reducing tumor aggressiveness and metastasis formation. Here, SORT1 is linked to neoplasm.